Novel pathway for NASH

CN Bio and Cambridge University identify a regulatory pathway that may be driving the problematic liver disease

Register for free to listen to this article
Listen with Speechify
CAMBRIDGE, U.K.—CN Bio, a cell culture company that has developed single and multi-organ microphysiological systems (MPS) that improve the accuracy and efficiency of drug discovery, has announced the publication of co-authored research led by researchers at the University of Cambridge in Nature Metabolism. The research identifies a novel pathway that regulates the underlying mechanism of non-alcoholic steatohepatitis (NASH), potentially a new therapeutic target. The collaborative work uses CN Bio’s NASH model to help elucidate the complex cellular mechanisms that cause liver fibrosis.
The group demonstrated that bone morphogenetic protein 8B (BMP8B), a poorly characterized member of the BMP/TGFß superfamily, exhibits marked upregulation during non-alcoholic fatty liver disease (NAFLD) progression to full-fledged NASH. This surge of BMP8B was shown to be an important mediator of liver disease progression, and a leading pathogenic mediator of the wound healing response of NASH, therefore presenting itself as a potential therapeutic target.
The paper illustrates the direct translation between CN Bio’s NASH assay, human clinical studies and in-vivo mouse models. It demonstrates that the MPS NASH model could offer more human-relevant data than standard liver tissue studies, and a quicker and cheaper option to study NASH pathophysiology with similar results to long and expensive animal models to better inform the drug discovery process and reduce associated costs.
Cell cultures were performed in CN Bio’s MPS NASH model, utilizing its proprietary liver-on-chip technology, which enables longer term in-vitro culture (greater than one month) of primary human hepatocytes in 3D microtissue structures. The NASH assay reportedly captures all key aspects of the different stages of the NAFLD/NASH spectrum: intracellular fat accumulation, inflammation and fibrosis.
“Increasing global levels of obesity are paralleled with growing numbers of NASH patients. However, currently there are no therapies on the market to treat the disease, with candidates in phase 3 clinical trials not effective enough to treat the majority of patients,” said Dr. David Hughes, CEO of CN Bio. “B providing human-relevant organ-on-chip data, our NASH model is enabling researchers to screen new NAFLD and NASH therapeutic candidates, investigate mechanisms of action and generate actionable data in weeks, ultimately to fast-track investigation into new drug candidates.”
 Added Dr. Tomasz Kostrzewski, director of biology at CN Bio: “This paper demonstrates how industry leaders in fatty liver disease, NASH and fibrosis have recognised the quality of CN Bio’s research and the reliability of our data. We’re excited to see this research published in Nature Metabolism, a new and exciting journal for our field which will become highly impactful.”
You can access the paper, “Bone morphogenetic protein 8B promotes the progression of non-alcoholic steatohepatitis,” at

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

DDN July 2024 Magazine Issue

Latest Issue  

• Volume 20 • Issue 4 • July 2024

July 2024

July 2024 Issue